234 related articles for article (PubMed ID: 30703376)
1. Buparlisib is a novel inhibitor of daunorubicin reduction mediated by aldo-keto reductase 1C3.
Bukum N; Novotna E; Morell A; Hofman J; Wsol V
Chem Biol Interact; 2019 Apr; 302():101-107. PubMed ID: 30703376
[TBL] [Abstract][Full Text] [Related]
2. Aldo-keto reductase 1C3 (AKR1C3): a missing piece of the puzzle in the dinaciclib interaction profile.
Novotná E; Büküm N; Hofman J; Flaxová M; Kouklíková E; Louvarová D; Wsól V
Arch Toxicol; 2018 Sep; 92(9):2845-2857. PubMed ID: 29992508
[TBL] [Abstract][Full Text] [Related]
3. Roscovitine and purvalanol A effectively reverse anthracycline resistance mediated by the activity of aldo-keto reductase 1C3 (AKR1C3): A promising therapeutic target for cancer treatment.
Novotná E; Büküm N; Hofman J; Flaxová M; Kouklíková E; Louvarová D; Wsól V
Biochem Pharmacol; 2018 Oct; 156():22-31. PubMed ID: 30077642
[TBL] [Abstract][Full Text] [Related]
4. Anthracycline resistance mediated by reductive metabolism in cancer cells: the role of aldo-keto reductase 1C3.
Hofman J; Malcekova B; Skarka A; Novotna E; Wsol V
Toxicol Appl Pharmacol; 2014 Aug; 278(3):238-48. PubMed ID: 24832494
[TBL] [Abstract][Full Text] [Related]
5. Selective inhibition of aldo-keto reductase 1C3: a novel mechanism involved in midostaurin and daunorubicin synergism.
Morell A; Novotná E; Milan J; Danielisová P; Büküm N; Wsól V
Arch Toxicol; 2021 Jan; 95(1):67-78. PubMed ID: 33025066
[TBL] [Abstract][Full Text] [Related]
6. Human dehydrogenase/reductase SDR family member 11 (DHRS11) and aldo-keto reductase 1C isoforms in comparison: Substrate and reaction specificity in the reduction of 11-keto-C
Endo S; Morikawa Y; Kudo Y; Suenami K; Matsunaga T; Ikari A; Hara A
J Steroid Biochem Mol Biol; 2020 May; 199():105586. PubMed ID: 31926269
[TBL] [Abstract][Full Text] [Related]
7. Interactions of antileukemic drugs with daunorubicin reductases: could reductases affect the clinical efficacy of daunorubicin chemoregimens?
Novotná E; Morell A; Büküm N; Hofman J; Danielisová P; Wsól V
Arch Toxicol; 2020 Sep; 94(9):3059-3068. PubMed ID: 32588086
[TBL] [Abstract][Full Text] [Related]
8. Instability of C154Y variant of aldo-keto reductase 1C3.
Endo S; Takada S; Honda RP; Müller K; Weishaupt JH; Andersen PM; Ludolph AC; Kamatari YO; Matsunaga T; Kuwata K; El-Kabbani O; Ikari A
Chem Biol Interact; 2017 Oct; 276():194-202. PubMed ID: 28025170
[TBL] [Abstract][Full Text] [Related]
9. In Silico and In Vitro Assessment of Carbonyl Reductase 1 Inhibition Using ASP9521-A Potent Aldo-Keto Reductase 1C3 Inhibitor with the Potential to Support Anticancer Therapy Using Anthracycline Antibiotics.
Jamrozik M; Piska K; Bucki A; Koczurkiewicz-Adamczyk P; Sapa M; Władyka B; Pękala E; Kołaczkowski M
Molecules; 2023 Apr; 28(9):. PubMed ID: 37175180
[TBL] [Abstract][Full Text] [Related]
10. Adipocytes Sequester and Metabolize the Chemotherapeutic Daunorubicin.
Sheng X; Parmentier JH; Tucci J; Pei H; Cortez-Toledo O; Dieli-Conwright CM; Oberley MJ; Neely M; Orgel E; Louie SG; Mittelman SD
Mol Cancer Res; 2017 Dec; 15(12):1704-1713. PubMed ID: 29117945
[TBL] [Abstract][Full Text] [Related]
11. Long-chain fatty acids inhibit human members of the aldo-keto reductase 1C subfamily.
Hara A; Endo S; Matsunaga T; Soda M; Yashiro K; El-Kabbani O
J Biochem; 2017 Nov; 162(5):371-379. PubMed ID: 28992312
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of AKR1B10-mediated metabolism of daunorubicin as a novel off-target effect for the Bcr-Abl tyrosine kinase inhibitor dasatinib.
Büküm N; Novotná E; Morell A; Želazková J; Laštovičková L; Čermáková L; Portillo R; Solich P; Wsól V
Biochem Pharmacol; 2021 Oct; 192():114710. PubMed ID: 34339712
[TBL] [Abstract][Full Text] [Related]
13. Quantitative Analysis of mRNA and Protein Expression Levels of Aldo-Keto Reductase and Short-Chain Dehydrogenase/Reductase Isoforms in the Human Intestine.
Hirosawa K; Fujioka H; Morinaga G; Fukami T; Ishiguro N; Kishimoto W; Nakase H; Mizuguchi H; Nakajima M
Drug Metab Dispos; 2023 Dec; 51(12):1569-1577. PubMed ID: 37722844
[TBL] [Abstract][Full Text] [Related]
14. Sex hormones reduce NNK detoxification through inhibition of short-chain dehydrogenases/reductases and aldo-keto reductases in vitro.
Stapelfeld C; Maser E
Chem Biol Interact; 2017 Oct; 276():167-173. PubMed ID: 28257955
[TBL] [Abstract][Full Text] [Related]
15. Potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitors based on the benzoisoxazole moiety: application of a bioisosteric scaffold hopping approach to flufenamic acid.
Pippione AC; Carnovale IM; Bonanni D; Sini M; Goyal P; Marini E; Pors K; Adinolfi S; Zonari D; Festuccia C; Wahlgren WY; Friemann R; Bagnati R; Boschi D; Oliaro-Bosso S; Lolli ML
Eur J Med Chem; 2018 Apr; 150():930-945. PubMed ID: 29602039
[TBL] [Abstract][Full Text] [Related]
16. A novel fluorometric assay for aldo-keto reductase 1C3 predicts metabolic activation of the nitrogen mustard prodrug PR-104A in human leukaemia cells.
Jamieson SM; Gu Y; Manesh DM; El-Hoss J; Jing D; Mackenzie KL; Guise CP; Foehrenbacher A; Pullen SM; Benito J; Smaill JB; Patterson AV; Mulaw MA; Konopleva M; Bohlander SK; Lock RB; Wilson WR
Biochem Pharmacol; 2014 Mar; 88(1):36-45. PubMed ID: 24434189
[TBL] [Abstract][Full Text] [Related]
17. Potent and Highly Selective Aldo-Keto Reductase 1C3 (AKR1C3) Inhibitors Act as Chemotherapeutic Potentiators in Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia.
Verma K; Zang T; Penning TM; Trippier PC
J Med Chem; 2019 Apr; 62(7):3590-3616. PubMed ID: 30836001
[TBL] [Abstract][Full Text] [Related]
18. In vitro evaluation of the reductive carbonyl idarubicin metabolism to evaluate inhibitors of the formation of cardiotoxic idarubicinol via carbonyl and aldo-keto reductases.
Bajraktari-Sylejmani G; Oster JS; Burhenne J; Haefeli WE; Sauter M; Weiss J
Arch Toxicol; 2024 Mar; 98(3):807-820. PubMed ID: 38175295
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of human carbonyl reducing enzymes by plant anthrone and anthraquinone derivatives.
Westermann M; Adomako-Bonsu AG; Thiele S; Çiçek SS; Martin HJ; Maser E
Chem Biol Interact; 2022 Feb; 354():109823. PubMed ID: 35065925
[TBL] [Abstract][Full Text] [Related]
20. Pathophysiological roles of autophagy and aldo-keto reductases in development of doxorubicin resistance in gastrointestinal cancer cells.
Matsunaga T; Kawabata S; Yanagihara Y; Kezuka C; Kato M; Morikawa Y; Endo S; Chen H; Iguchi K; Ikari A
Chem Biol Interact; 2019 Dec; 314():108839. PubMed ID: 31563593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
